Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial

Key Points Bendamustine-rituximab therapy results in high overall and CR rates with sustained remissions in CAD. Bendamustine plus rituximab may be considered in first line for most patients with CAD requiring therapy.